

Oncology Today with Dr Neil Love: Current and Future Management of  
HER2-Altered Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate confirmed objective response rate for patients with advanced non-small cell lung cancer (NSCLC) who received T-DXd at the dose of 5.4 mg/kg in the DESTINY-Lung02 study?
  - a. 15%
  - b. 31%
  - c. 49%**
  - d. 76%
  - e. 100%
2. What is the mechanism of action of zongertinib?
  - a. Tyrosine kinase inhibitor (TKI) targeting both HER2 and EGFR
  - b. HER2-specific, EGFR-sparing TKI**
  - c. HER2-sparing, EGFR-specific TKI
3. What was the approximate overall response rate in patients with advanced NSCLC who received zongertinib in cohort 1 of the Beamion LUNG-1 study?
  - a. 16%
  - b. 30%
  - c. 53%
  - d. 71%**
  - e. 100%
4. What was the most commonly reported any-grade adverse event in patients with advanced NSCLC who received zongertinib in cohort 1 of the Beamion LUNG-1 study?
  - a. Neutropenia
  - b. Diarrhea**
  - c. Anemia
  - d. Constipation
  - e. Alopecia
5. What was the approximate objective response rate in patients with advanced NSCLC that received sevabertinib in cohort D of the SOHO-01 study?
  - a. 18%
  - b. 31%
  - c. 49%
  - d. 64%**
  - e. 100%